The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents. The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both interindividual and intraindividual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system. The implications inferred by these observations aforementioned bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a genetic model to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNV's will be delineated. From a clinical perspective, the importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in diagnostic categories and of maintaining equilibrium between individual difficulties and competencies and environmental demands will be discussed.
| INTRODUCTION
Ever since the first reports of psychotic disorders in individuals with the 22q11.2 deletion (22q11DS) were published, now some 25 years ago, there has been increasing interest in this remarkable association (Bassett et al., 1998; Murphy, Jones, & Owen, 1999; Pulver et al., 1994; Shprintzen, Goldberg, Golding-Kushner, & Marion, 1992) . These initial findings have been replicated in several studies, confirming an approximately 25-fold increased risk of developing schizophrenia in patients with 22q11DS compared to a 1% lifetime risk in the general population (McGrath, Saha, Chant, & Welham, 2008) . Understandably, this observed association continues to receive much attention from both clinicians and investigators. From a clinical perspective the increased risk mandates careful monitoring of patients, in particular during adolescence and early adulthood, when the risk of psychotic development is highest. From a research perspective the association represents the strongest known genetic risk for schizophrenia conferred by a single genetic variant (Van, Boot, & Bassett, 2017) . In addition, the phenotypic expression of schizophrenia in 22q11DS has been described as indiscernible from schizophrenia in the general population (Bassett et al., 2003; Chow, Watson, Young, & Bassett, 2006 ). These observations have spurred the research community to examine 22q11DS as a unique genetically homogeneous model for schizophrenia , and, in the words of Thomas Insel: initiate prospective studies of this population that will provide "important insights into the trajectory from risk to disorder" (Insel, 2010) .
While the emphasis on schizophrenia and associated psychotic disorders (commonly referred to as "schizophrenia spectrum") in 22q11DS is clearly justified (McDonald-McGinn et al., 2015) , a potential downside of a highly specific focus may be that the occurrence of other neuropsychiatric phenotypes in individuals with this genetic disorder can be easily overlooked. Multiple independent studies indicate significantly increased rates of a number of psychiatric and other neurodevelopmental disorders (including anxiety, autism spectrum, attention deficit disorders) in addition to schizophrenia in individuals with 22q11DS (Antshel et al., 2006; Jolin et al., 2009; Niklasson, Rasmussen, Oskarsdottir, & Gillberg, 2009; Schneider, Debbane, et al., 2014a; Vorstman et al., 2006) . This article will review the current knowledge of these phenotypes in 22q11DS, with a focus on childhood and adolescence. In addition, potential pitfalls regarding these findings will be examined, including the effect of ascertainment bias and possible limitations of categorical diagnostic classifications. Furthermore, both research and clinical care implications of the neuropsychiatric phenotypes in 22q11DS will be discussed.
| NEURODEVELOPMENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE

| Overview of the neuropsychiatric and cognitive phenotype
The neurodevelopmental and psychiatric phenotype of children and adolescents with 22q11DS is highly diverse. From infancy onward, delayed and/or impaired speech and language development are frequently observed (Swillen et al., 1999) . Moreover, intellectual functioning in the borderline range (FSIQ between 70 and 85) is most common, followed by mild intellectual disability (FSIQ 55 and 70).
More severe levels of intellectual disability are uncommon in children, but more frequently observed in adults with 22q11DS (De Smedt et al., 2007; Evers, De Die-Smulders, Smeets, Clerkx, & Curfs, 2009; Swillen et al., 1999) suggesting that cognitive abilities may not be stable in all individuals with 22q11DS. Indeed, a recent longitudinal study found that, overall, individuals with 22q11DS showed a modest but significant decline in IQ between the ages of 8 and 24 . Notably, in those who developed a psychotic disorder, the decline, most pronounced in verbal IQ, was significantly steeper compared to those without a psychotic disorder. These findings provide evidence that cognitive decline might be a useful early clinical marker of psychotic disorders in people with 22q11DS .
The international brain and behavior consortium (IBBC) on 22q11DS has provided the most comprehensive overview of psychopathology in individuals with 22q11DS to date (Schneider, Debbane, et al., 2014a) . This first study from this multicenter consortium reported on the psychopathology of 1,401 individuals with 22q11DS, recruited across multiple sites, aged 6-68 (mean = 18,78, SD = 10,66) Schneider, Debbane, et al., 2014a) . Figure 1 presents a summary of the findings across three different age groups between 6 and 25 years. Developmental disorders such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are reported more frequently in the younger age groups as compared to the older groups (see also : Antshel et al., 2006; Niklasson et al., 2009; Vorstman et al., 2006) . Disruptive disorders are relatively less frequent overall, and their prevalence declines with increasing age.
Mood disorders are frequently observed, and notably their prevalence increases significantly over time, particularly for major depressive disorder. Anxiety disorders are frequently reported across all age groups, but are especially prevalent in children and adolescents (see also : Jolin et al., 2009 
| The specificity of the psychiatric and neurodevelopmental profile in 22q11DS
Observations from epidemiological studies indicate that the overall rate of psychopathology is increased in youth with idiopathic intellectual impairment (Einfeld, Ellis, & Emerson, 2011 (6 through 17 years) compared to observations in individuals with idiopathic intellectual impairment (n = 641) (Emerson & Hatton, 2007) and the general population.
It is important to note that prevalence rates reported in Table 1 are all to some extent influenced by variable degrees of ascertainment and/or assessment biases and should, therefore, be compared with caution. For instance, individuals in the idiopathic intellectual impairment group were not recruited through a clinical site and intellectual impairment was established based on parental/teacher report. In contrast, many studies contributing to the overview of 22q11DS findings were conducted at a clinical site (see discussion below) and in many individuals IQ was obtained through formal testing. Rates reported in the general population are not specific for youth.
Notwithstanding these precautions, some preliminary insights can be gained from Table 1 . First, from this young age onwards, psychotic disorders occur in the 22q11DS population (between age 13 and 17 years the rate is already 10%). Many individuals fall into the diagnostic category "psychotic disorder not otherwise specified," likely due to the young age at assessment. Second, the prevalence of other developmental disorders (ASD and ADHD) and mood/anxiety disorders is increased in 22q11DS youth over what is observed in a population with idiopathic intellectual impairment. Third, the rate of disruptive disorders in people with 22q11DS is well below the rate in the idiopathic intellectual impairment population. These findings suggest that the 22q11.2 deletion has a specific impact on the behavioral phenotype and, therefore, that the risk of psychopathology cannot be solely explained as an unspecific consequence of intellectual impairment (Figure 2 , scenario A).
Further support for the proposition that the observed increased rates of psychopathology are specific to 22q11DS (Figure 2 , scenario B), as opposed to a nonspecific effect of broad intellectual impairment, is provided by studies that show no correlation between cognitive level and the risk for psychiatric disorders in individuals with 22q11DS (Evers et al., 2014; Niarchou et al., 2014) . Accordingly, higher rates of psychopathology are reported in 22q11DS individuals compared to IQ-matched controls (Jansen et al., 2007) . Inversely, the lower than expected prevalence rates of both disruptive disorders (albeit higher than in the general population, see Table 1 ) and substance use disorders in 22q11DS (Vingerhoets et al., under review), compared to both general and idiopathic intellectually impaired populations (Carroll Chapman & Wu, 2012; Swerts et al., 2017) provide further evidence for a specific genetic effect. These findings suggest that scenario B (Figure 2 ) is likely-although it does not exclude some effect by the mechanism of scenario A altogether. Furthermore, findings suggest that 22q11DS increases the risk of some psychiatric Figure 1 since we collapsed data obtained in the age range 6 to 17 years, most individuals assessed at a level of mild intellectual disability). b Data from (Emerson & Hatton, 2007) (641 individuals, age range 5 to 16 years, intellectual impairment based on parental/teacher report, most individuals estimated at a level of mild intellectual disability, the numbers represent point prevalence (i.e., symptoms present during the monthhalf year preceding the assessment). c Data from cohorts including both children and adolescents were used to obtain these estimates; exact age ranges vary between the different studies. disorders, but not of others. Indeed, similar to observations in cohorts with other structural pathogenic variants, emerging evidence indicates that specific profiles of psychopathology can be distinguished when comparing 22q11DS to idiopathic, unselected populations (Bruining et al., 2014; Smith, Barker, Seltzer, Abbeduto, & Greenberg, 2012) .
| Understanding the high degree of phenotypic variability 2.3.1 | Neuropsychiatric pleiotropy
The psychiatric phenotypic expression of 22q11DS is highly variable.
Many different psychiatric disorders are associated with this CNV, phenotypes can differ considerably between individuals, and differences exist across age groups. This variability is consistent with the phenomenon of phenotypic pleiotropy observed in many rare CNV's (Bassett, Scherer, & Brzustowicz, 2010; Vorstman & Ophoff, 2013) , whereby one specific genetic variant can result in independent phenotypic expressions. For example, in the context of 22q11DS, the presence or absence of congenital cardiac problems does not seem to be associated with an altered risk for psychotic disorders (Bassett & Chow, 2008) . Therefore, congenital cardiac defects and psychotic disorders can be considered as true pleiotropic manifestations of the 22q11.2 deletion.
Observations from numerous studies suggest that in 22q11DS different psychiatric phenotypes can also emerge independently, as pleiotropic conditions. The distinction between true pleiotropy and "pseudopleiotropy" is important in this regard. The latter refers to phenotypes that are observed as separate manifestations, whereas in reality they represent the same pathological process, for instance at different developmental stages (Vorstman, Breetvelt, Thode, Chow, & Bassett, 2013) . Prospective longitudinal studies can provide insight in this regard. For example, a recent study found evidence for true pleiotropy regarding ASD and psychotic disorders, given that individuals with 22q11DS with ASD at a young age were not at an increased risk for developing psychotic disorders later in life compared to those without ASD (Fiksinski et al., 2017; . On the other hand, cognitive decline (Duijff et al., 2012) and psychotic disorders in 22q11DS were initially reported as two different phenotypes, while subsequent prospective studies indicated that these two phenotypes represent, at least in a subset of individuals, the same pathological process but at different developmental stages , thereby providing an example of pseudopleiotropy. Such findings underline the importance of considering additional factors that may influence the observed phenotypic variability. Here, we will briefly discuss such factors, including the phenomena of geneenvironment interactions, cross-site ascertainment and assessment differences, age-dependent phenotypes, and diagnostic classification artifacts that impact the observed comorbidity.
| Environmental factors as a source of interindividual variability
Several studies point toward the impact of environmental factors on the observed behavioral phenotype in individuals with 22q11DS. For example, studies have shown that lower parental socio-economic-status (SES) and intrusive parenting style (Barber, 2002) were associated with worse social functioning and other clinically significant problems in children with 22q11DS (Allen et al., 2014; Shashi et al., 2010) . Additional evidence is provided by a study examining the effect of Sept5 deficiency (one of the genes in the 22q11.2 region) on social functioning in a mice model of 22q11DS (Harper et al., 2012) . This study showed that Sept5 deficient mice had decreased affiliative social interactions compared to wild type mice. Interestingly, Sept5 deficient male mice exposed to individual housing were characterized by reduced anxiety and increased affiliative social interactions compared to mice exposed to group-housing, thereby showing a significant gene-environment interaction. Although more research is needed in this regard, such emerging evidence points to complex interactions between genetic and environmental factors as a source of phenotypic variability among individuals with 22q11DS.
| Ascertainment and assessment bias
The IBBC studies (Schneider, Debbane, et al., 2014a) A recent epidemiological Danish nation-wide study of 22q11DS and 22q11.2 duplication syndrome offers a different perspective, as a population-based study. This study included 244 adult individuals with 22q11DS identified through case registration in a population of 3,768,943. The reported patterns of developmental and psychiatric disorders in 22q11DS, compared to 24,400 age-and gender-matched population controls, were similar to what is described in clinically ascertained 22q11DS cohorts, but, as expected, with somewhat lower prevalence rates (Hoeffding et al., 2017) .
The IBBC studies also varied with regard to the diagnostic assessment tools they employed and comorbid mental health problems screened (Schneider, Debbane, et al., 2014a) . For example, not all sites used instruments to assess at risk status for psychotic disorders or standardized assessment for autism. Consequently, some of the differences in prevalence rates reported from different sites may be, at least partly, explained by differences in ascertainment and assessment (biases) across sites. In individuals with 22q11DS, the variability observed across age groups can be inherent to phenotypic characteristics such as typical age of onset, consistent with observations in the general population. For example, in patient cohorts under the age of 18, one would not expect to find a high prevalence of schizophrenia spectrum disorders, as the first psychotic episode typically emerges in late adolescence/early adulthood (Owen, Sawa, & Mortensen, 2016) . Differences in typically conducted psychiatric assessments across age groups may also contribute to the phenotypic variability reported across different ages. Standard adult psychiatric assessment often does not include screening for developmental disorders such as ASD or ADHD. In cohorts assessed as adults, one would, therefore, not expect to find a high prevalence of such developmental disorders, while in reality a portion of these individuals might have been diagnosed as such, had their psychiatric assessment-either as children or adults-included screening for these developmental disorders.
With increasing awareness of ASD and ADHD in adults and associated clinical service developments, however, (Murphy et al., 2016) , the reported prevalence of ASD and ADHD in adults with 22q11DS may change in future reports.
Not only can psychiatric conditions emerge as an individual matures, certain psychiatric disorders or neurodevelopmental presentations may also improve over time. Indeed, our clinical impression suggests that in some individuals with 22q11DS with a previous childhood neurodevelopmental diagnosis, improvement occurs to such extent that a diagnostic classification may no longer be justified in adulthood (e.g., ADHD or ASD), which is consistent with what is observed in idiopathic populations with such neurodevelopmental disorders (e.g., Fein et al., 2013; Woolfenden, Sarkozy, Ridley, & Williams, 2012) . The finding that in a sample of 70 individuals with 22q11DS 30% of those previously diagnosed attention deficit disorder (ADD) did not manifest sufficient symptoms justifying an ADD diagnosis at follow-up assessment (Antshel et al., 2010) provides preliminary evidence in this regard. Although such latematuration trajectories are observed only in a minority of individuals with 22q11DS, they are relevant and warrant further study.
| The pitfalls of a categorical approach to the psychiatric phenotype in 22q11DS
From both a clinical and a research perspective, employing a categorical diagnostic classification system has merits, as it provides clinicians and researchers with a shared vocabulary. However, a too stringent adherence to such a categorical, dichotomous approach to psychopathology also has substantial limitations. While this is relevant to all psychiatric populations, several observations in the 22q11DS population render the consideration of such potential limitations particularly salient for these individuals. On the one hand, it may result in the application of several diagnostic labels to account for a relatively small set of symptoms, while on the other hand clinically relevant but isolated symptoms may not readily fit in any diagnostic category and thus be overlooked (Baker & Vorstman, 2012) . For example, much higher prevalence rates of psychotic symptoms (25%) than of psychotic disorders (10%) are observed in adolescents with 22q11DS (Schneider et al., 2016; Vorstman et al., 2006) . Importantly, such symptoms, though not reflected in an individual's psychiatric diagnosis, may still be relevant in understanding an individual's profile of difficulties and competencies, as well as in implementing adequate treatment and preventive strategies.
| IMPLICATIONS FOR RESEARCH
| 22q11DS as a genetic model for schizophrenia
Several aspects of 22q11DS make this genetic disorder a highly appealing model to investigate neuroscientific questions, particularly the etiology of schizophrenia . The highly increased risk for this illness in 22q11DS patients, and the opportunity to identify individuals early in life based on their genetic diagnosis has allowed investigators to study clinical and biological correlates of the developmental trajectory of schizophrenia. Moreover, a unique and easily overlooked aspect of these studies is that they are conducted in a genetically relatively homogeneous context, that is, all individuals share the same 22q11.2 deletion, which can be assumed to be the cause of their high vulnerability for schizophrenia. In contrast, the broad and largely unknown genetic heterogeneity of schizophrenia hampers studies in unselected general population cohorts. Recent studies confirm the usefulness of 22q11DS as a human genetic model to unravel the gene x environment interactions leading to schizophrenia (Insel, 2010) . Importantly, the psychopathological path leading to transition to psychosis in 22q11DS (Schneider et al., 2016; Weisman et al., 2017) is broadly comparable to that observed in other clinical high risk samples (Fusar-Poli et al., 2013) . More specifically, the subthreshold psychotic symptoms and the Clinical High Risk (CHR) for psychosis criteria, previously developed in the general population (Fusar-Poli et al., 2013) , are reliable and also applicable in the 22q11DS population.
| 22q11DS exemplifies the need for dimensional and repeated assessment approaches
Up until now, subclassifying individuals with 22q11DS by psychiatric diagnoses has not proven particularly useful in delineating underlying neurogenetic mechanisms. Indeed, it has been proposed that despite the divergence in diagnostic classifications, observations from different studies in 22q11DS converge into a limited number of symptom domains (Baker & Vorstman, 2012) . Furthermore, preliminary associations have been described between genetic factors and symptoms dimensions that cut across existing diagnostic categories (Bassett, Caluseriu, Weksberg, Young, & Chow, 2007; Raux et al., 2007; Shashi et al., 2006) . These and other studies underscore the potential added value of broad dimensional, quantitative and repeated assessments as a means toward a more dimensional perspective on mental health equilibrium and the risk of psychopathology (Nelson, McGorry, Wichers, Wigman, & Hartmann, 2017) .
| 22q11DS as a model for neuropsychiatric pleiotropy in rare copy number variants
The high variability of neuropsychiatric phenotypes observed in 22q11DS represents another unique research opportunity. The past decade has witnessed the discovery of a growing list of pathogenic genetic variants, including copy number variants (CNVs) (Malhotra & Sebat, 2012) and rare single nucleotide variants (SNVs) (Yuen et al., 2017) . Typically, the prevalence of each of these pathogenic variants is rare, but when present in an individual they can confer a substantial risk. The picture emerging from neuropsychiatric studies in individuals carrying these rare high impact variants is remarkably similar to what is observed in 22q11DS: a high degree of neuropsychiatric variability with increased rates of different disorders including schizophrenia, anxiety, ADHD, ASD and affective disorders, and varying levels of cognitive impairment (Vorstman & Ophoff, 2013) . Examples include, but are not limited to, the 3q29 deletion, which is associated with various neuropsychiatric disorders including anxiety and mood disorders and schizophrenia (Glassford et al., 2016) , and the 16p11.2 deletion, associated with intellectual disability, ASD, and schizophrenia (Moreno-De-Luca et al., 2015) . Quantifying the risk of the different associated disorders and understanding how they emerge across the lifespan is essential to improve counseling and clinical care for individuals carrying these rare but high impact genetic variants . To this end, studies are needed to investigate for each of these rare pathogenic genetic variants to what extent there is true neuropsychiatric pleiotropy, the age-dependent emergence of certain phenotypes, and the possible influence of classification artifacts and ascertainment bias. In addition, it will be key to identify factors, both genetic and environmental, that modulate the different neuropsychiatric outcomes. Similarly, early phenotypic characteristics should be studied as potential markers for poor functional outcome. However, such studies are severely hampered by the fact that each of these variants occurs at extremely low rates in the population, impeding the collection of sufficiently powered samples.
It is in this context that the 22q11.2 deletion syndrome provides a unique research opportunity. Its prevalence is high (estimated 1/2,000-4,000) (McDonald-McGinn et al., 2015) and its genetic description in the early 1980s (McDonald-McGinn et al., 2015) has preceded by approximately two decades the much more recent discovery of the majority of other rare pathogenic genetic variants associated with psychiatric phenotypes (Malhotra & Sebat, 2012 ). This has afforded 22q11DS studies a significant advance over studies on other pathogenic variants. Indeed, at present, multiple cohorts of several hundreds of individuals with 22q11DS are examined in research institutes across the world. Findings of 22q11DS studies show the potential of using early phenotypic characteristics to identify subgroups with poor functional outcome (Schneider, Van der Linden, et al., 2014b) , and indicate several early potential biomarkers of psychotic disorder (Bakker et al., 2016; Padula et al., 2017; Ramanathan et al., 2016; Raux et al., 2007; Scariati, Padula, Schaer, & Eliez, 2016; Tomescu et al., 2014) . The IBBC has pooled phenotypic data from over 22 sites which together amount to well over 1,800 individuals with 22q11DS. This sample size, unprecedented in any other study on rare genetic variants with neuropsychiatric impact, allows the investigation of aforementioned questions with sufficient statistical power.
| IMPLICATIONS FOR CLINICAL CARE
| Need for regular psychiatric assessments
International guidelines for clinical care for individuals with 22q11DS mandate regular psychiatric and cognitive assessment (Bassett et al., 2011) , understandably so, considering the overall high rates of psychopathology in this patient population. The observations reviewed in this article provide several directions in this regard. Psychiatric symptoms and disorders in 22q11DS may either remain constant over time, they may emerge or intensify (e.g., psychotic disorders), or they may be outgrown and no longer be valid as individuals mature. Cognitive abilities may not be stable in a subgroup of patients and a decline in verbal IQ may indicate increased risk of developing a psychotic disorder . In order to maintain accuracy in describing an individual's neuropsychiatric profile (and thereby allowing individualized mental healthcare) this time-related phenotypic variability needs to be considered and, consequently, repeated psychiatric and neuropsychological assessments are required.
Emerging mental, rather than physical, health concerns are more likely to bring adolescents and young adults with 22q11DS to medical attention (Fung et al., 2015; McDonald-McGinn et al., 2015; Schneider et al., 2016; Swillen, 2016) . Despite increasing awareness of the importance of planned transitions for young people with neurodevelopmental disorders to adult health and social care (American Academy of Pediatrics; American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine, 2002; Stewart, 2009; Young, Murphy, & Coghill, 2011) , there is limited investigation of how best to do this (Belling et al., 2014; Paul, Street, Wheeler, & Singh, 2015) and future research is warranted. However, best practice guidelines for young people with 22q11DS should include a planned transition of mental health care (including psychiatric and cognitive assessments if resources allow) across different life stages and stressors. Examples include when moving from primary to secondary school and from adolescent to adult health care.
With respect to all clinical recommendations for individuals with 22q11DS, including the need for regular psychiatric assessments and the importance of a guided transition to adulthood, there is the necessity to acknowledge, investigate, and work toward overcoming the obstacles to implementing such recommendations. While there is consensus regarding the importance of discussing risk for psychiatric disorders in these individuals repeatedly throughout different stages of life (Bassett et al., 2011; Hercher & Bruenner, 2008) , studies have reported that, for various possible reasons including stigma, other medical issues requiring attention and a young age at time of counseling, at present such discussions are insufficiently implemented in most clinical settings (Baughman, Morris, Jensen, & Austin, 2015; Morris, Inglis, Friedman, & Austin, 2013) .
| Need to look beyond diagnostic categories
Full-blown developmental and psychiatric disorders occur and may necessitate pharmacological or cognitive-behavioral therapeutic interventions in individuals with 22q11DS. However, the myriad of clinically relevant symptoms in these individuals is not always sufficiently captured in diagnostic classification categories. When symptoms are under-recognized or occur in isolation (i.e., in the absence of usually co-occurring symptoms critical for a diagnostic classification), they will not be reflected in an individual's psychiatric diagnosis. Such symptoms may have significant impact on an individual's daily functioning, but will remain unrecognized if only diagnostic categories are taken into account. In psychiatric assessments of individuals with 22q11DS, careful attention should, therefore, be paid not only to psychiatric diagnoses, but also to symptomatology as this may be important for lifestyle adaptations and professional care and (symptomatic) treatment. Taking symptom domains into consideration is pivotal in understanding an individual's profile of competencies and difficulties (Baker & Vorstman, 2012; Beaton & Simon, 2011) . Delineating such a profile is highly informative in finding and/or creating an environment that is optimally adapted to the individual. (Yui et al., 1999) . Indeed, high levels of anxiety in youth with 22q11DS have been proposed as a predictor of transition to psychosis (Gothelf et al., 2013) , which supports the hypothesized importance of stress. In light of the 20-25% risk for developing schizophrenia and related psychotic disorders that individuals with 22q11DS have, optimal care should be taken to avoid stress. Creating and maintaining a balance between their neurocognitive, social and behavioral profile and environmental demands is essential in this regard.
| CONCLUSION
The 22q11.2 deletion exemplifies the fast emerging novel class of rare pathogenic genetic variants as identifiable etiologies in the field of psychiatry, which raises important new challenges with immediate relevance for both researchers and clinicians. The early discovery of this rare CNV in the 1980s however, has allowed a time advantage over the majority of the other, more recently identified pathogenic rare variants. Consequently, implications from studies on 22q11DS are not limited to this genetic disorder, but can also contribute to the understanding of phenomena observed in other rare pathogenic variants, including the high variability and variable expression of associated phenotypes.
In addition to the well-established risk for schizophrenia, individuals with 22q11DS are at increased risk for a wide range of psychopathology from early childhood onwards. To some extent, this phenotypic variability may be an artifact of forcing the observed symptoms into our current diagnostic classifications. In addition, variable assessment and ascertainment methods are bound to further contribute to differences between studies. However, notwithstanding these caveats, several observations from 22q11DS studies begin to stand out. it is important to maintain an optimal balance between individual abilities and environmental expectations. A global low cognitive level (IQ), but also specific (and sometimes covert) relative weaknesses in cognitive domains and neurodevelopmental functions (e.g., attention, information processing, social and communicative abilities, and sensitivity to sensory input) can contribute to chronic stress due to demands that exceed abilities. The clinical importance is twofold. First, such a situation is undesirable in itself as it causes discomfort and stress to any person. Second, numerous studies indicate that stress may play a role in the course of schizophrenia. While such evidence is not yet robustly available in the 22q11DS population, it is possible that in the context of a high genetic risk, high levels of stress may contribute to the expression of schizophrenia. 
